Back to Trials
NCT07218705Recruiting

A Study Of MCG In Cardiac Amyloidosis

Mayo Clinic

Start Date

12/3/2025

Completion Date

11/1/2027

Summary

The primary objective of this observational study is to evaluate the utility of magnetocardiography (MCG) in diagnosing and monitoring disease progression in patients with amyloidosis, and to assess its effectiveness in comparison to other modalities, such as ECG.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria 1. Age ≥ 18 years on the date of consent 2. Ability for participant to comply with study requirements 3. Written informed consent Exclusion Criteria 1. Pregnant or breastfeeding 2. Having an active atrial fibrillation episode as seen on most current 12-lead ECG 3. Active thoracic metal implants (including pacemaker, insertable cardiac monitor, or internal defibrillator). 4. External electrical pads or devices (e.g. Pacer pads, ECG electrodes, heart rate patch), that must remain on patient's chest during MCG scan 5. Inability to lie down in a supine/inclined position and stay still on the examination bed 6. Clinical conditions that in the opinion of the Investigator would compromise the safety of the patient or ability to complete the protocol

Interventions

DEVICE

SandboxAQ CardiAQ Magnetocardiography

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Amyloidosis

Locations

Mayo Clinic in Rochester

Rochester, Minnesota 55905

United States